Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Psychopharmacology

• Publication date

  1998-03-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1007/s002130050551PMID 9551772
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics

  2004cited by this paper
• The role of serotonin in the pathophysiology and treatment of schizophrenia.

  1997cited by this paper
• Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET

  1997cited by this paper
• Atypical Neuroleptics Have Low Affinity for Dopamine D2 Receptors or Are Selective for D4 Receptors

  1997cited by this paper
• A PET Study of 5-HT2 and D2 Dopamine Receptor Occupancy Induced by Olanzapine in Healthy Subjects

  1997cited by this paper
• Expression of D1 receptor mRNA in projections from the forebrain to the ventral tegmental area

  1997cited by this paper
• Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses.

  1997cited by this paper
• Electrophysiological Effects of Olanzapine, a Novel Atypical Antipsychotic, on A9 and A10 Dopamine Neurons

  1996cited by this paper
• Differential expression of c-fos mRNA in rat prefrontal cortex, striatum, N. accumbens and lateral septum after typical and atypical antipsychotics: an in situ hybridization study.

  1996cited by this paper
• Radioreceptor Binding Profile of the Atypical Antipsychotic Olanzapine

  1996influential reference
• On the In‐vivo Modulation of Neostriatal Dopamine Release by Fluoxetine and 5−Hydroxy‐L‐tryptophan in Conscious Rats

  1996cited by this paper
• Olanzapine: a new typical antipsychotic drug.

  1996cited by this paper
• Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial.

  1996cited by this paper
• Regional differences in the effect of haloperidol and atypical neuroleptics on interstitial levels of DOPAC in the rat forebrain: an in vivo microdialysis study

  1996cited by this paper
• Dopamine receptors and brain function.

  1996cited by this paper
• Olanzapine: A New Atypical Antipsychotic Drug

  1996cited by this paper
• Effects of Olanzapine on Regional C-Fos Expression in Rat Forebrain

  1996cited by this paper
• Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, α1-adrenergic and muscarinic receptors in vivo in rats

  1996cited by this paper
• Local Influence of Endogenous Norepinephrine on Extracellular Dopamine in Rat Medial Prefrontal Cortex

  1995cited by this paper
• The selective 5-HT2A receptor antagonist, MDL 100,907, increases dopamine efflux in the prefrontal cortex of the rat.

  1995cited by this paper
• New Insights into the Biology of Schizophrenia through the Mechanism of Action of Clozapine

  1995cited by this paper
• Effects of typical and atypical neuroleptics on Fos protein expression in the rat forebrain.

  1994cited by this paper
• Biochemical evidence for the regulation of central noradrenergic activity by 5-HT1A and 5-HT2 receptors: microdialysis studies in the awake and anaesthetized rat.

  1994cited by this paper
• The role of D1-dopamine receptor in working memory: local injections of dopamine antagonists into the prefrontal cortex of rhesus monkeys performing an oculomotor delayed-response task.

  1994cited by this paper
• Effect of scopolamine on the efflux of dopamine and its metabolites after clozapine, haloperidol or thioridazine.

  1994cited by this paper
• The Effect of Clozapine on Plasma Norepinephrine: Relationship to Clinical Efficacy

  1994cited by this paper
• Brain region effects of clozapine on amino acid and monoamine transmission.

  1994cited by this paper
• Effects of olanzapine and other antipsychotic agents on responding maintained by a conflict schedule

  1994cited by this paper
• Blockade of D‐1 dopamine receptors in the medial prefrontal cortex produces delayed effects on pre‐ and postsynaptic indices of dopamine function in the nucleus accumbens

  1994cited by this paper
• Differential Effects of Locally Administered Clozapine and Haloperidol on Dopamine Efflux in the Rat Prefrontal Cortex and Caudate‐Putamen

  1994cited by this paper
• Schizophrenia research moves to the prefrontal cortex.

  1994cited by this paper
• Cerebral cortical mechanisms in schizophrenia

  1994cited by this paper
• Prazosin modulates the firing pattern of dopamine neurons in rat ventral tegmental area.

  1993cited by this paper
• Prefrontal cortex regulates burst firing and transmitter release in rat mesolimbic dopamine neurons studied in vivo.

  1993cited by this paper
• The regulation of subcortical dopamine systems by the prefrontal cortex: interactions of central dopamine systems and the pathogenesis of schizophrenia.

  1992influential reference
• The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent.

  1992cited by this paper
• SCH 39166, a potential antipsychotic drug, does not evoke movement disorders in cebus monkeys.

  1992cited by this paper
• Effect of fluoxetine on serotonin and dopamine concentration in microdialysis fluid from rat striatum.

  1992cited by this paper
• Prefrontal cortical efferents in the rat synapse on unlabeled neuronal targets of catecholamine terminals in the nucleus accumbens septi and on dopamine neurons in the ventral tegmental area

  1992cited by this paper
• The mechanism of action of novel antipsychotic drugs.

  1991cited by this paper
• Utilization of microdialysis for assessing the release of mesotelencephalic dopamine following clozapine and other antipsychotic drugs.

  1990cited by this paper
• The prefrontal cortex in schizophrenia and other neuropsychiatric diseases: in vivo physiological correlates of cognitive deficits.

  1990cited by this paper
• A new and highly sensitive method for measuring 3-methoxytyramine using HPLC with electrochemical detection. Studies with drugs which alter dopamine metabolism in the brain.

  1990cited by this paper
• Effects of buspirone and its metabolite, 1-(2-pyrimidinyl)piperazine, on brain monoamines and their metabolites in rats.

  1989cited by this paper
• The effects of clozapine and fluperlapine on the in vivo release and metabolism of dopamine in the striatum and in the prefrontal cortex of freely moving rats.

  1989cited by this paper
• The rat brain in stereotaxic coordinates (2nd edn): by George Paxinos and Charles Watson, Academic Press, 1986. £40.00/$80.00 (264 pages) ISBN 012 547 6213

  1987cited by this paper
• Implications of normal brain development for the pathogenesis of schizophrenia.

  1987cited by this paper
• In vivo potencies of antipsychotic drugs in blocking alpha 1 noradrenergic and dopamine D2 receptors: implications for drug mechanisms of action.

  1986cited by this paper
• Sequence and significance of dopamine metabolism in the rat brain.

  1985cited by this paper
• Effect of neuroleptic drugs on striatal dopamine release and metabolism in the awake rat studied by intracerebral dialysis.

  1984influential reference
• Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons

  1983influential reference
• Effect of prazosin on norepinephrine concentration and turnover in rat brain and heart.

  1978cited by this paper

• Augmentation Therapy With Serotonin 5‐HT1A Receptor Partial Agonists on Cognitive Function in Depressive Disorders: A Systematic Review of Randomized Controlled Studies

  2025cites this paper
• Effect of 5-HT1A receptor partial agonists of the azapirone class as an add-on therapy on psychopathology and cognition in schizophrenia: A systematic review and meta-analysis.

  2023cites this paper
• Augmentation therapy with serotonin1A receptor partial agonists on neurocognitive function in schizophrenia: A systematic review and meta-analysis

  2023cites this paper
• Potential Mechanisms for Why Not All Antipsychotics Are Able to Occupy Dopamine D3 Receptors in the Brain in vivo

  2022cites this paper
• GPCR-Based Dopamine Sensors—A Detailed Guide to Inform Sensor Choice for In Vivo Imaging

  2020cites this paper
• Dopaminergic impact of cART and anti-depressants on HIV Neuropathogenesis in older adults.

  2019cites this paper
• Access to the CNS: Biomarker Strategies for Dopaminergic Treatments

  2018cites this paper
• Melatonin attenuates behavioural deficits and reduces brain oxidative stress in a rodent model of schizophrenia.

  2017cites this paper
• Risperidone and aripiprazole alleviate prenatal valproic acid-induced abnormalities in behaviors and dendritic spine density in mice

  2017cites this paper
• Priming locus coeruleus noradrenergic modulation of medial perforant path-dentate gyrus synaptic plasticity.

  2017cites this paper
• Comparative effects of sertraline, haloperidol or olanzapine treatments on ketamine-induced changes in mouse behaviours

  2017cites this paper
• Ketamine-induced behavioural and brain oxidative changes in mice: an assessment of possible beneficial effects of zinc as mono- or adjunct therapy

  2017cites this paper
• The influence of aripiprazole and olanzapine on neurotransmitters level in frontal cortex of prenatally stressed rats.

  2016cites this paper
• Evidence for Noncanonical Neurotransmitter Activation: Norepinephrine as a Dopamine D2-Like Receptor Agonist

  2016cites this paper
• Product Data Sheet Chemical Properties Product

  2016cites this paper
• The effects in rats of lisdexamfetamine in combination with olanzapine on mesocorticolimbic dopamine efflux, striatal dopamine D2 receptor occupancy and stimulus generalization to a D-amphetamine cue.

  2016cites this paper
• The alpha2C-adrenoceptor as a neuropsychiatric drug tar-get - PET studies in human subjects

  2015cites this paper
• Pharmacological depletion of serotonin in the basolateral amygdala complex reduces anxiety and disrupts fear conditioning.

  2015cites this paper
• Pharmacological Treatment of Cognitive Dysfunction in Neuropsychiatric Disorders

  2015cites this paper
• The atypical effects of olanzapine on body weight regulation

  2015influential citation
• Frontal lobe function and social adjustment in patients with schizophrenia: near‐infrared spectroscopy

  2015cites this paper
• Efficacy of Olanzapine for Treating Depressive Episodes in Bipolar Disorder

  2014cites this paper
• Teratogenic Effects of Coadministration of Fluoxetine and Olanzapine on Rat Fetuses

  2014cites this paper
• L‐DOPA‐induced dyskinesia in a rat model of Parkinson's disease is associated with the fluctuational release of norepinephrine in the sensorimotor striatum

  2014cites this paper
• Comparative effect of lurasidone and blonanserin on cortical glutamate, dopamine, and acetylcholine efflux: role of relative serotonin (5‐HT)2A and DA D2 antagonism and 5‐HT1A partial agonism

  2014cites this paper
• Efficacy and Tolerability of Pharmacotherapy Options for the Treatment of Irritability in Autistic Children

  2014cites this paper
• The effect of risperidone on the mirtazapine-induced changes in extracellular monoamines in the rat frontal cortex

  2014cites this paper
• Clozapine effects on adenylyl cyclase activity and serotonin type 1A receptors in human brain post-mortem

  2014cites this paper
• Effects of olanzapine and betahistine co-treatment on serotonin transporter, 5-HT2A and dopamine D2 receptor binding density.

  2013cites this paper
• Schizophrenia: causes and treatments.

  2013cites this paper
• Effectiveness of Short-Term Olanzapine in Patients With Bipolar I Disorder, With or Without Comorbidity With Substance Use Disorder

  2013cites this paper
• Effect of risperidone on the fluoxetine-induced changes in extracellular dopamine, serotonin and noradrenaline in the rat frontal cortex

  2013cites this paper
• Utility of Combined Treatment with Antipsychotic and Antidepressant Drugs: Scientific Rationales and Clinical Implications

  2013cites this paper
• Mode of action of asenapine vs. other antipsychotic drugs : an experimental analysis

  2012cites this paper
• Deuterium-L-DOPA: a Novel Means to Improve Treatment of Parkinson's Disease

  2012cites this paper
• Effects of Olanzapine and Clozapine on Radial Maze Performance in Naive and MK-801-Treated Mice

  2012cites this paper
• Muscarinic mechanisms in psychotic disorders.

  2012cites this paper
• Typical and Atypical Antipsychotic Drugs Increase Extracellular Histamine Levels in the Rat Medial Prefrontal Cortex: Contribution of Histamine H1 Receptor Blockade

  2012influential citation
• Metabolomic profiling to identify potential serum biomarkers for schizophrenia and risperidone action.

  2011cites this paper
• Mirtazapine in combination with perospirone synergistically enhances dopamine release in the rat prefrontal cortex via 5‐HT1A receptor activation

  2011cites this paper
• Treatment of the Psychostimulant‐Sensitized Animal Model of Schizophrenia

  2011cites this paper
• Effects of olanzapine on extracellular concentrations and tissue content of neurotensin in rat brain regions.

  2011cites this paper
• Effect of augmentation with olanzapine in outpatients with depression in partial remission with melancholic features: Consecutive case series

  2011cites this paper
• Role of 5-HT6 receptor in conditioned learning and memory

  2011cites this paper
• Haloperidol modulates noradrenergic responses to aversive stimulation depending on treatment duration.

  2011cites this paper
• Effects of olanzapine, sertindole and clozapine on MK-801 induced visual memory deficits in mice.

  2011cites this paper
• Phencyclidine-induced Loss of Asymmetric Spine Synapses in Rodent Prefrontal Cortex is Reversed by Acute and Chronic Treatment with Olanzapine

  2011cites this paper
• Selective enhancement of mesocortical dopaminergic transmission by noradrenergic drugs: therapeutic opportunities in schizophrenia.

  2011cites this paper
• β1‐Adrenergic receptors activate two distinct signaling pathways in striatal neurons

  2011cites this paper
• Effects of a novel mGlu2/3 receptor agonist prodrug, LY2140023 monohydrate, on central monoamine turnover as determined in human and rat cerebrospinal fluid

  2011cites this paper
• A Double-Blind, Randomized, and Placebo-Controlled Trial of Buspirone Added to Risperidone in Patients With Chronic Schizophrenia

  2010cites this paper
• In vivo temporal EPR study using a region-selected intensity determination method to estimate cerebral reducing ability in rats treated with olanzapine.

  2010cites this paper
• Role of adrenoceptors in the regulation of dopamine/DARPP‐32 signaling in neostriatal neurons

  2010cites this paper
• Effect of CFMTI, an allosteric metabotropic glutamate receptor 1 antagonist with antipsychotic activity, on Fos expression in regions of the brain related to schizophrenia.

  2010cites this paper
• Different patterns of longitudinal changes in plasma levels of catecholamine metabolites and brain-derived neurotrophic factor after administration of atypical antipsychotics in first episode untreated schizophrenic patients

  2010cites this paper
• Metabotropic glutamate mGlu1 receptor stimulation and blockade: therapeutic opportunities in psychiatric illness.

  2010cites this paper
• Unraveling monoamine receptors involved in the action of typical and atypical antipsychotics on glutamatergic and serotonergic transmission in prefrontal cortex.

  2010cites this paper
• Olanzapine causes hypothermia, inactivity, a deranged feeding pattern and weight gain in female Wistar rats.

  2010cites this paper
• Reboxetine Enhances the Olanzapine-Induced Antipsychotic-Like Effect, Cortical Dopamine Outflow and NMDA Receptor-Mediated Transmission

  2010cites this paper
• In vivo pharmacology of the dopaminergic stabilizer pridopidine.

  2010cites this paper
• Mechanisms for the Interaction of Dopamine and Norepinephrine in the Prefrontal Cortex: Implications for the Treatment of Cognitive Symptoms of Schizophrenia

  2010cites this paper
• Molecular mechanisms underlying synergistic effects of SSRI–antipsychotic augmentation in treatment of negative symptoms in schizophrenia

  2009cites this paper
• Schizophrenia treatment. Critical review on the drugs and mechanisms of action of antipsychotics.

  2009cites this paper
• Associations between betel nut (Areca catechu) and symptoms of schizophrenia among patients in Nepal: A longitudinal study.

  2009cites this paper
• Modeling cholinergic aspects of schizophrenia: focus on the antimuscarinic syndrome.

  2009cites this paper
• Treatment of cognitive dysfunction in chronic schizophrenia by augmentation of atypical antipsychotics with buspirone, a partial 5‐HT1A receptor agonist

  2009cites this paper
• F15063, a potential antipsychotic with dopamine D2/D3 receptor antagonist, 5-HT1A receptor agonist and dopamine D4 receptor partial agonist properties: influence on neuronal firing and neurotransmitter release.

  2009cites this paper
• Tyrosine availability modulates potassium-induced striatal catecholamine efflux in vivo.

  2008cites this paper
• 6‐Hydroxydopamine lesion in the ventral tegmental area fails to reduce extracellular dopamine in the cerebral cortex

  2008cites this paper
• Antipsychotic Drugs: Comparison in Animal Models of Efficacy, Neurotransmitter Regulation, and Neuroprotection

  2008influential citation
• Switching schizophrenia patients from typical neuroleptics to olanzapine: effects on BOLD response during attention and working memory.

  2008cites this paper
• Differential effects of olanzapine, haloperidol and risperidone on calcitonin gene-related peptide in the rat brain.

  2008cites this paper
• Dopamine Depletion of the Prefrontal Cortex Induces Dendritic Spine Loss: Reversal by Atypical Antipsychotic Drug Treatment

  2008cites this paper
• Augmentation with olanzapine in TCA‐refractory depression with melancholic features: a consecutive case series

  2008influential citation
• Atomoxetine increases histamine release and improves learning deficits in an animal model of attention-deficit hyperactivity disorder: the spontaneously hypertensive rat.

  2008cites this paper
• Enhanced efficacy of both typical and atypical antipsychotic drugs by adjunctive alpha2 adrenoceptor blockade: experimental evidence.

  2007cites this paper
• Lipogenic effects of antipsychotic drugs in cultured cells and in rat

  2007cites this paper
• Chronic high-dose haloperidol has qualitatively similar effects to risperidone and clozapine on immediate-early gene and tyrosine hydroxylase expression in the rat locus coeruleus but not medial prefrontal cortex.

  2007cites this paper
• In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders

  2007influential citation
• Molecular targets for treating cognitive dysfunction in schizophrenia.

  2007cites this paper
• PHARMACOGENETIQUE DE LA SCHIZOPHRENIE

  2007cites this paper
• Dopamine and Noradrenaline Coupling in the Cerebral Cortex

  2007influential citation
• Pharmacotherapy of Schizophrenia

  2007cites this paper
• 5-HT6 receptor antagonist SB-399885 potentiates haloperidol and risperidone-induced dopamine efflux in the medial prefrontal cortex or hippocampus.

  2007cites this paper
• ACP-103, a 5-Hydroxytryptamine 2A Receptor Inverse Agonist, Improves the Antipsychotic Efficacy and Side-Effect Profile of Haloperidol and Risperidone in Experimental Models

  2007cites this paper
• Effects of olanzapine on plasma levels of catecholamine metabolites, cytokines, and brain-derived neurotrophic factor in schizophrenic patients

  2007influential citation
• Propranolol blocks chronic risperidone treatment-induced enhancement of spatial working memory performance of rats in a delayed matching-to-place water maze task

  2007influential citation
• Atypical Antipsychotic Drugs: Mechanism of Action

  2007cites this paper
• Improvement of Prefrontal Brain Function in Endogenous Psychoses Under Atypical Antipsychotic Treatment

  2007cites this paper
• On the origin of cortical dopamine: is it a co-transmitter in noradrenergic neurons?

  2006cites this paper
• Fluvoxamine as an adjunctive agent in schizophrenia.

  2006cites this paper
• Cambio de haloperidol a olanzapina en una muestra de pacientes peruanos esquizofrénicos con extrapiramidalismo

  2006cites this paper
• Extracellular dopamine levels are lower in the medial prefrontal cortex of alcohol-preferring rats compared to Wistar rats.

  2006cites this paper
• Comparing sertindole to other new generation antipsychotics on preferential dopamine output in limbic versus striatal projection regions: Mechanism of action

  2006influential citation
• Differential effects of haloperidol, clozapine and olanzapine on learning and memory functions in mice.

  2006cites this paper
• Parallel regulation by olanzapine of the patterns of expression of 5-HT2A and D3 receptors in rat central nervous system and blood cells.

  2006cites this paper
• Effect of the attention deficit/hyperactivity disorder drug atomoxetine on extracellular concentrations of norepinephrine and dopamine in several brain regions of the rat.

  2006cites this paper
• Olanzapine-Induced Suppression of Cocaine Self-Administration in Rhesus Monkeys

  2006influential citation
• Effects of short-term and chronic olanzapine treatment on immediate early gene protein and tyrosine hydroxylase immunoreactivity in the rat locus coeruleus and medial prefrontal cortex.

  2006cites this paper
• Augmentation by citalopram of risperidone-induced monoamine release in rat prefrontal cortex

  2006cites this paper